Most teams don’t lose on science—they lose on timing.
In generic and biosimilar development, the “go/no-go” decision is often framed as a technical question: Can we make it? Can we prove it? Can we hit the right endpoints?
But the real inflection p…

Designing Around the Moat: How Generic Developers Can Think About Secondary Formulation Patents
In generic drug development, the “moat” is rarely just the primary patent. It’s often the secondary layer—formulation tweaks, process changes, stability imp…

The Potential Risks of Combining Vascepa with Blood Thinners: What You Need to Know As the medical community continues to… https://www.Drugchatter.com/chat/17808/are-there-any-potential-side-effects-of-combining-vascepa-with-blood-thinners/

Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…

Brands Don’t Launch “Competition” by Accident—They Do It to Control the Next Phase of the Market
There’s a quiet strategy playing out across pharma that most investors only notice after the damage is done: the authorized generic.
On the surface, it loo…

Dairy-Free Alternatives to Lipitor: Exploring Options for Statin-Free Heart Health As the world becomes increasingly aware… https://www.Drugchatter.com/chat/1561/are-there-any-dairy-free-alternatives-to-lipitor/

Pick the Right FDA Pathway—and You Own the Market. Pick the Wrong One—and You’re Funding Your Competitor.
In pharma, the most expensive mistake isn’t a failed clinical trial. It’s a strategic misstep that happens after the science is done—when you choo…